Abstract
The asbestos induced cancer malignant mesothelioma (MM) is difficult to diagnose and has a poor prognosis. MM is an immunological cancer, therefore autoantibodies may be suitable biomarkers and associated with prognosis. We used Protoarray® microarrays to determine immune responses to 8798 antigens in 10 MM and 10 asbestos exposed controls and developed diagnostic panels using 17 antigens from this. The AUC of these panels were independently tested in these 10 MM patients and controls and in a validation group of 36 controls and 35 MM patients using luminex assays; none of the antigens identified were validated. Immune responses to RAB38 were associated with a better prognosis.
Acknowledgements
The authors acknowledge the contribution of Life Technologies scientists to this study for performing the protoarray and luminex assays and for the identification of the diagnostic panels described in the manuscript.
Disclosure statement
The authors report no declarations of interest.
Funding information
This study was supported by the National Health and Medical Research Council (NHMRC) of Australia project grant 106637, NHMRC Clinical Research Excellence grant 1001020 and the Insurance Commission of Western Australia.